Once-weekly Subcutaneous Semaglutide 2.4 mg Reduces Body Weight in Adults with Overweight or Obesity Regardless of Baseline Characteristics (STEP 1)
In this medfyle
Expert commentary by Karen SL Lam, MD
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
Acknowledgements
This is a highlights summary of an oral session given at the ENDO 2021 and presented by:
Robert Kushner, MD
Division of Endocrinology, Feinberg School of Medicine, Northwestern University
Chicago, IL, USA
The content is produced by Infomedica, the official reporting partner of ENDO 2021. The summary text was drafted by Patrick Moore, PhD, and reviewed by Marco Gallo, MD, an independent external expert, and approved by Raghu Mirmira, MD, PhD, the scientific editor of the program.
The presenting authors of the original session had no part in the creation of this conference highlights summary.
In addition, an expert commentary on the topic has been provided by:
Karen SL Lam, MD
Chair Professor in Medicine
The University of Hong Kong, HK
About the Expert
Karen SL Lam, MD
Chair Professor in Medicine
The University of Hong Kong, HK
Dr. Lam is Chair Professor in Medicine, Rosie TT Young Professor in Endocrinology & Metabolism, and Clinical Director of the State Key Laboratory of Pharmaceutical Biotechnology, at the University of Hong Kong. She leads a clinical and translational research program focusing on the prediction of obesity-related diseases, especially cardiovascular diseases, type 2 diabetes and its complications, through research on adipocyte-derived hormones, genetics and long-term cohort studies.
References
1. Kushner RF, Calanna S, Davies M, et al. Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. Obesity (Silver Spring). 2020;28(6):1050-1061.
2. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989.
